PhD
Professor, Center for Integrative Chemical Biology and Drug Discovery
Eshelman School of Pharmacy
UNC-Chapel Hill
Molecular Therapeutics
Area of Interest
We are interested in developing drug leads/candidates for new targets including kinase, phosphate kinase and protein targets identified by UNC faculty and external investigators. We have successfully used the structure- and/or ligand-based drug design approaches to deliver compounds to clinic (MerTK inhibitors) or licensing (IDH1 inhibitor, co-developed with NCATs). We will continue to apply the similar approaches for drug discovery towards new targets.
